Anti-CD19 immunotoxin enhances the activity of chemotherapy in severe combined immunodeficient mice with human pre-B acute lymphoblastic leukemia.
The anti-CD19 immunotoxin (IT) (HD37-dgRTA) is effective in killing B-lineage leukemia cells and in curing severe combined immunodeficient mice with acute lymphoblastic leukemia. The present study aimed to identify effective combinations of HD37-dgRTA and chemotherapeutic agents. The in-vitro cytotoxicity assays demonstrate that the combination of HD37-dgRTA and either daunorubicin or vincristine is effective. The in-vivo experiments using HD37-dgRTA with vincristine prolonged the survival of mice compared to the chemotherapeutic agent or IT (90.7 vs. 147.1 days). Also, 80% of the mice treated with IT plus vincristine were long-term survivors.
Herrera
L
L
Department of Pediatrics, Division of Hematology/Oncology, Temple University Children's Medical Center, Temple University School of Medicine, Philadelphia, PA 19140, USA. larryh@temple.edu
Stanciu-Herrera
C
C
Morgan
C
C
Ghetie
V
V
Vitetta
E S
ES
D000818:Animals; D000906:Antibodies / Q000276:immunology*; D018941:Antigens, CD19 / Q000276:immunology*; D002051:Burkitt Lymphoma / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology* / Q000473:pathology; D045744:Cell Line, Tumor; D004247:DNA / Q000096:biosynthesis; D006801:Humans; D000922:Immunotoxins / Q000276:immunology*; D008297:Male; D051379:Mice; D016513:Mice, SCID; D015996:Survival Rate
D000906:Antibodies; D018941:Antigens, CD19; D000922:Immunotoxins; D004247:DNA